Copyright (c) 2022 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Rapid and Stable Liquid Chromatographic Tandem Mass Spectrometric Method for Simultaneous Estimation of Pioglitazone, Keto Pioglitazone and Hydroxy Pioglitazone in Human Plasma: Application to Bioequivalence Study
Corresponding Author(s) : Shruti Chopra
Asian Journal of Chemistry,
Vol. 34 No. 11 (2022): Vol 34 Issue 11, 2022
Abstract
High performance liquid chromatographic tandem mass spectrometric method for the determination of pioglitazone, keto pioglitazone (M-III) and hydroxy pioglitazone (M-IV) in human plasma has been developed and validated using pioglitazone-D4, keto pioglitazone-D4 and hydroxy pioglitazone-D5 as internal standards. Solid phase extraction was carried out for sample preparation to extract analyte and internal standard from human plasma. The extracted sample was injected through autosampler in HPLC connected with Hypersil Gold, 100 mm × 4.6 mm, 5 μm using mobile phase consisting of methanol:solution A:solution B - 80:10:10 v/v/v). Pioglitazone, keto pioglitazone (M-III) and hydroxy pioglitazone (M-IV) were chromatographically separated and detected using the MS detector. The best-fit lines using weighting factor (1/concentration2) linear least square regression analysis were obtained by peak area ratio of pioglitazone, keto pioglitazone (M-III) and hydroxy pioglitazone (M-IV) with their internal standards pioglitazone-D4, keto pioglitazone-D4 and hydroxy pioglitazone-D5, respectively. This report provides the results of various validation parameters including stability studies and extended precision and accuracy which is required for long study samples batch analysis. This analytical method is valid for the determination of pioglitazone in the range of 18.9 ng/mL to 2994.4 ng/mL), keto pioglitazone (M-III) (3.23 ng/mL to 512.60 ng/mL), hydroxy pioglitazone (M-IV) 10.1 ng/mL to 1603.8 ng/mL) and using pioglitazone-D4, keto pioglitazone-D4, hydroxy pioglitazone-D5, respectively as internal standards in human plasma using a Hypersil Gold, 100 mm × 4.6 mm, 5 μm column.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- S. Suzuki, Y. Mori, A. Nagano, A. N. Ito, Y. Nagayasu, M. Kobayashi, H. Kato, T. Kuno and S. Takahashi, Int. J. Mol. Sci., 17, 2071 (2016); https://doi.org/10.3390/ijms17122071
- C.J. Bailey and C. Day, Br. J. Diabetes Vasc. Dis., 1, 7 (2001); https://doi.org/10.1177/14746514010010010201
- P. de Pablos-Velasco, Expert Rev. Cardiovasc. Ther., 8, 1057 (2010); https://doi.org/10.1586/erc.10.98
- A. Al-Majed, A.H.H. Bakheit, H.A. Abdel Aziz, H. Alharbi and F.I. AlJenoobi, Profiles Drug Subst. Excip. Relat. Methodol., 41, 379 (2016); https://doi.org/10.1016/bs.podrm.2015.11.002
- D.A. Eckland and M. Danhof, Exp. Clin. Endocrinol. Diabetes, 108(Suppl. 2), 234 (2000); https://doi.org/10.1055/s-2000-8525
- K. Yamashita, H. Murakami, O. Teruaki and M. Motohashi, J. Chromatogr. B Biomed. Sci. Appl., 677, 141 (1996); https://doi.org/10.1016/0378-4347(95)00440-8
- P. Sripalakit, P. Neamhom and A. Saraphanchotiwitthaya, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 843, 164 (2006); https://doi.org/10.1016/j.jchromb.2006.05.032
- X. Zhang, Y. Peng, P. Wan, L. Yin, G. Wang and J. Sun, J. Chromatogr. Sci., 52, 52 (2014); https://doi.org/10.1093/chromsci/bms204
- Z.J. Lin, W. Ji, D. Desai-Krieger and L. Shum, J. Pharm. Biomed. Anal., 33, 101 (2003); https://doi.org/10.1016/S0731-7085(03)00344-3
- Y.J. Xue, K.C. Turner, J.B. Meeker, J. Pursley, M. Arnold and S. Unger, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 795, 215 (2003); https://doi.org/10.1016/S1570-0232(03)00575-0
- M. Kawaguchi-Suzuki, F. Bril, P.P. Sanchez, K. Cusi and R.F. Frye, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 969, 219 (2014); https://doi.org/10.1016/j.jchromb.2014.08.019
- Guidance for Industry/Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), May (2001).
References
S. Suzuki, Y. Mori, A. Nagano, A. N. Ito, Y. Nagayasu, M. Kobayashi, H. Kato, T. Kuno and S. Takahashi, Int. J. Mol. Sci., 17, 2071 (2016); https://doi.org/10.3390/ijms17122071
C.J. Bailey and C. Day, Br. J. Diabetes Vasc. Dis., 1, 7 (2001); https://doi.org/10.1177/14746514010010010201
P. de Pablos-Velasco, Expert Rev. Cardiovasc. Ther., 8, 1057 (2010); https://doi.org/10.1586/erc.10.98
A. Al-Majed, A.H.H. Bakheit, H.A. Abdel Aziz, H. Alharbi and F.I. AlJenoobi, Profiles Drug Subst. Excip. Relat. Methodol., 41, 379 (2016); https://doi.org/10.1016/bs.podrm.2015.11.002
D.A. Eckland and M. Danhof, Exp. Clin. Endocrinol. Diabetes, 108(Suppl. 2), 234 (2000); https://doi.org/10.1055/s-2000-8525
K. Yamashita, H. Murakami, O. Teruaki and M. Motohashi, J. Chromatogr. B Biomed. Sci. Appl., 677, 141 (1996); https://doi.org/10.1016/0378-4347(95)00440-8
P. Sripalakit, P. Neamhom and A. Saraphanchotiwitthaya, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 843, 164 (2006); https://doi.org/10.1016/j.jchromb.2006.05.032
X. Zhang, Y. Peng, P. Wan, L. Yin, G. Wang and J. Sun, J. Chromatogr. Sci., 52, 52 (2014); https://doi.org/10.1093/chromsci/bms204
Z.J. Lin, W. Ji, D. Desai-Krieger and L. Shum, J. Pharm. Biomed. Anal., 33, 101 (2003); https://doi.org/10.1016/S0731-7085(03)00344-3
Y.J. Xue, K.C. Turner, J.B. Meeker, J. Pursley, M. Arnold and S. Unger, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 795, 215 (2003); https://doi.org/10.1016/S1570-0232(03)00575-0
M. Kawaguchi-Suzuki, F. Bril, P.P. Sanchez, K. Cusi and R.F. Frye, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 969, 219 (2014); https://doi.org/10.1016/j.jchromb.2014.08.019
Guidance for Industry/Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), May (2001).